- In February 2025, Stemline Therapeutics announced the global expansion of Elzonris (tagraxofusp-erzs), the first FDA-approved CD123-targeted therapy for BPDCN, to additional markets including Brazil, South Korea, and select EU countries. This expansion is expected to improve access to frontline targeted therapy, strengthening the company’s global footprint and improving patient outcomes in previously underserved regions.
- In October 2024, Jazz Pharmaceuticals launched a clinical development program for its next-generation CD123 x CD3 bispecific antibody designed specifically for relapsed or refractory BPDCN. This investigational therapy is aimed at enhancing T-cell mediated cytotoxicity with a better safety profile, offering a promising alternative to current therapies and marking a significant innovation in immunotherapeutic approaches.
- In August 2024, AbbVie announced the initiation of a Phase II trial evaluating its novel BCL-2 inhibitor, navitoclax, in combination with hypomethylating agents for BPDCN patients unfit for intensive chemotherapy. This combination is being studied for its potential to induce apoptosis in malignant dendritic cells and expand treatment options for elderly or high-risk patients.
- In May 2024, Genentech (a member of the Roche Group) launched preclinical studies of a CD123-directed antibody-drug conjugate (ADC) for BPDCN under its hematologic malignancy pipeline. This ADC is engineered to deliver a cytotoxic payload directly to CD123-expressing cells, offering a highly selective and potent mechanism of action aimed at improving remission rates in early-stage trials
